Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
ML-210
Cat. No.:
OB0225LY-0041
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
ML-210 is a small, potent inhibitor of the protein kinase CK1, known to modulate various cellular processes including circadian rhythms and Wnt signaling.
Synonym:
1360705-96-9; ML 210; [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone
CAS No.:
1360705-96-9
Compound CID:
49766530
Formula:
C22H20Cl2N4O4
Formula Weight:
475.32
Specification
Relative Density:
1.415 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ML-210 can be used to explore CK1 functionally relevant pathways.
Library Information
Targets:
Ras; Metabolic enzymes; Glutathione peroxidase
Receptors:
Gpx4
Pathways:
MAPK; GPCR/G protein; Oxidation-reduction; Apoptosis; Metabolism
Plate Number:
AOCL-1
Plate Location:
e3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
11 mg/mL; 23.14 mM
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.1 mg/mL (2.31 mM)
